Tango Therapeutics Inc (TNGX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Tango Therapeutics Inc   (NASDAQ: TNGX)


Tango Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Tango Therapeutics Inc's ROI in the second quarter of 2026?
Tango Therapeutics Inc recorded a cumulative net loss of $-124 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -24.21%.

Within the Healthcare sector 336 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3494 to 3585.

Definition and Formula of Return on Investment



Return On Investment (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 98.54 % 1.62 % -22.35 % -33.97 % -28.63 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 1,054 421 377 192 198
Return On Investment (TTM) -24.21 % -36.1 % -40.44 % -44.36 % -56.56 %
TNGX's Overall Ranking # 3585 # 3494 # 2596 # 1213 # 3373
Seq. Investment Change TTM 72.03 % 18.22 % 10.89 % -11.96 % -11.95 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -124 -107 -102 -101 -146




Return On Investment TNGX's Ranking
Within: No.
Industry # 126
Sector # 337
Overall # 3585

Return On Investment Statistics
High Average Low
-1.83 %
-28.3 %
-56.56 %
(Jun 30 2021)   (Jun 30 2025)







Financial Statements
Tango Therapeutics Inc's II. Quarter Investments $ 1,054 Millions TNGX's Balance sheet
Tango Therapeutics Inc's II. Quarter Income $ -55 Millions Quarterly TNGX's Income Statement
TNGX's Income by Division See TNGX's Income by Division


TNGX Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 377 278 357 381 459
Y / Y Investment Growth 35.46 % -21.96 % -6.38 % -17.09 % 1014.12 %
Net Income in Millions -102 -130 -102 -108 -58
Y / Y Net Income Growth - - - - -
Annual Return On Investment -26.95 % -46.82 % -28.53 % -28.4 % -12.67 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
TNGX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for TNGX's Competitors
Subscribers only: Roi for Tango Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for TNGX's Customers

Other Ratios
TNGX's Roa TNGX's Inventory Turnover Ratio TNGX's Growth Rates TNGX's Dividend Statistics
TNGX's Profitability Ratios TNGX's Asset Turnover Ratio TNGX's Dividend Growth
TNGX's Roe TNGX's Valuation Ratios TNGX's Financial Strength Ratios TNGX's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI


Date modified: 2026-09-05T15:35:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.